The CD103+ tumor-specific T cells signified an important prognostic marker with improved OS, and the evaluation of the tissue-resident CD103+CD8+T cells might help assess the status of TME in HCC and ICC. This evidence concerns the gene CD8A and hepatocellular carcinoma.